Access the full text.
Sign up today, get DeepDyve free for 14 days.
L. Luznik, P. O'Donnell, H. Symons, Allen Chen, M. Leffell, M. Zahurak, Ted Gooley, S. Piantadosi, M. Kaup, R. Ambinder, C. Huff, W. Matsui, J. Bolaños-Meade, I. Borrello, Jonathan Powell, Elizabeth Harrington, Sandra Warnock, M. Flowers, R. Brodsky, B. Sandmaier, R. Storb, Richard Jones, E. Fuchs (2008)
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 14 6
S. Solomon, M. Sanacore, Xu Zhang, Stacey Brown, K. Holland, L. Morris, A. Bashey (2014)
Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 20 11
H. Sibai, Umberto Falcone, U. Deotare, F. Michelis, J. Uhm, Vikas Gupta, J. Kuruvilla, J. Lipton, M. Seftel, H. Messner, Dennis Kim (2016)
Myeloablative versus Reduced-Intensity Conditioning in Patients with Myeloid Malignancies: A Propensity Score-Matched Analysis.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 22 12
I. Walker, T. Panzarella, S. Couban, F. Couture, G. Devins, M. Elemary, Geneviève Gallagher, Holly Kerr, J. Kuruvilla, Stephanie Lee, J. Moore, T. Nevill, G. Popradi, J. Roy, K. Schultz, D. Szwajcer, C. Toze, R. Foley (2016)
Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial.The Lancet. Oncology, 17 2
A. Bashey, Xu Zhang, C. Sizemore, K. Manion, Stacey Brown, H. Holland, L. Morris, S. Solomon (2013)
T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 10
A. Bacigalupo, T. Lamparelli, G. Barisione, P. Bruzzi, S. Guidi, P. Alessandrino, P. Bartolomeo, R. Oneto, B. Bruno, N. Sacchi, M. Lint, A. Bosi (2006)
Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 12 5
L. Luznik, P. O'Donnell, E. Fuchs (2012)
Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation.Seminars in oncology, 39 6
L. Luznik, J. Bolaños-Meade, M. Zahurak, Allen Chen, B. Smith, R. Brodsky, C. Huff, I. Borrello, W. Matsui, Jonathan Powell, Y. Kasamon, Steven Goodman, A. Hess, Hyam Levitsky, R. Ambinder, Richard Jones, E. Fuchs (2010)
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.Blood, 115 16
J. Russell, W. Irish, A. Balogh, M. Chaudhry, M. Savoie, A. Turner, L. Larratt, J. Storek, N. Bahlis, C. Brown, D. Quinlan, M. Geddes, Nancy Zacarias, A. Daly, P. Duggan, D. Stewart (2010)
The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 16 4
K. Bradstock, I. Bilmon, J. Kwan, K. Micklethwaite, E. Blyth, S. Deren, A. Bayley, V. Gebski, D. Gottlieb (2015)
Single-Agent High-Dose Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Human Leukocyte Antigen-Matched Reduced-Intensity Peripheral Blood Stem Cell Transplantation Results in an Unacceptably High Rate of Severe Acute Graft-versus-Host Disease.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 21 5
J. Kanakry, Y. Kasamon, J. Bolaños-Meade, I. Borrello, R. Brodsky, E. Fuchs, N. Ghosh, D. Gladstone, C. Gocke, C. Huff, C. Kanakry, L. Luznik, W. Matsui, Huzefa Mogri, L. Swinnen, H. Symons, Richard Jones, R. Ambinder (2013)
Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 19 10
J. Finke, W. Bethge, C. Schmoor, H. Ottinger, M. Stelljes, A. Zander, L. Volin, T. Ruutu, D. Heim, R. Schwerdtfeger, K. Kolbe, J. Mayer, J. Maertens, W. Linkesch, E. Holler, V. Koza, M. Bornhäuser, H. Einsele, H. Kolb, H. Bertz, M. Egger, O. Grishina, G. Socié (2009)
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.The Lancet. Oncology, 10 9
Bone Marrow Transplantation (2018) 53:361–365 https://doi.org/10.1038/s41409-017-0053-9 CORRESPONDENCE Reduction of severe acute graft-versus-host disease using a combination of pre transplant anti-thymocyte globulin and post-transplant cyclophosphamide in matched unrelated donor transplantation 1 2 1 1 1 ● ● ● ● ● Uday Deotare Eshetu G. Atenafu David Loach Fotios V. Michelis Dennis (Dong-Hwan) Kim 1 1 1 1 ● ● ● Santhosh Thyagu Jeffrey H. Lipton Hans A. Messner Auro Viswabandya Received: 2 May 2017 / Revised: 6 October 2017 / Accepted: 23 October 2017 / Published online: 21 December 2017 © Macmillan Publishers Limited, part of Springer Nature 2018 Use of Post-transplant Cyclophosphamide (PTCy) has associated with severe forms of GVHD. Here we present recently been introduced specifically in the haplo-identical the preliminary outcome in our unrelated patients using transplant setting with promising results [1]. This inter- this regimen. vention has also shown a significant reduction of acute This is a retrospective study of the patient cohort treated graft versus host disease (aGVHD) and a trend towards from 1 October 2015 until 31 March 2016 in a single center. improving chronic graft versus host disease (cGVHD) [2]. This study was approved by the institutional Research The efficacy of PTCy has
Bone Marrow Transplantation – Springer Journals
Published: Dec 21, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.